FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285394928> ?p ?o ?g. }

• W4285394928 endingPage "5347" @default.
• W4285394928 startingPage "5336" @default.
• W4285394928 abstract "Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease. With response to neoadjuvant chemo-radiotherapy being a major prognostic factor, trial SAKK 41/16 assessed potential benefits of adding regorafenib to capecitabine-amplified neoadjuvant radiotherapy in LARC patients.Patients received regorafenib at three dose levels (40/80/120 mg once daily) combined with capecitabine 825 mg/m2 bidaily and local radiotherapy. We developed population pharmacokinetic models from plasma concentrations of capecitabine and its metabolites 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine as well as regorafenib and its metabolites M-2 and M-5 as implemented into SAKK 41/16 to assess potential drug-drug interactions (DDI). After establishing parent-metabolite base models, drug exposure parameters were tested as covariates within the respective models to investigate for potential DDI. Simulation analyses were conducted to quantify their impact.Plasma concentrations of capecitabine, regorafenib and metabolites were characterized by one and two compartment models and absorption was described by parallel first- and zero-order processes and transit compartments, respectively. Apparent capecitabine clearance was 286 L/h (relative standard error [RSE] 14.9%, interindividual variability [IIV] 40.1%) and was reduced by regorafenib cumulative area under the plasma concentration curve (median reduction of 45.6%) as exponential covariate (estimate -4.10 × 10-4 , RSE 17.8%). Apparent regorafenib clearance was 1.94 L/h (RSE 12.1%, IIV 38.1%). Simulation analyses revealed significantly negative associations between capecitabine clearance and regorafenib exposure.This work informs the clinical development of regorafenib and capecitabine combination treatment and underlines the importance of studying potential DDI with new anticancer drug combinations." @default.
• W4285394928 created "2022-07-14" @default.
• W4285394928 creator A5006238207 @default.
• W4285394928 creator A5014858344 @default.
• W4285394928 creator A5015387543 @default.
• W4285394928 creator A5018676268 @default.
• W4285394928 creator A5022167252 @default.
• W4285394928 creator A5023510680 @default.
• W4285394928 creator A5025804381 @default.
• W4285394928 creator A5033591303 @default.
• W4285394928 creator A5037441803 @default.
• W4285394928 creator A5071805546 @default.
• W4285394928 creator A5080158628 @default.
• W4285394928 creator A5082379986 @default.
• W4285394928 creator A5089216656 @default.
• W4285394928 date "2022-07-23" @default.
• W4285394928 modified "2023-10-01" @default.
• W4285394928 title "Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)" @default.
• W4285394928 cites W1965479467 @default.
• W4285394928 cites W1971827763 @default.
• W4285394928 cites W1984026103 @default.
• W4285394928 cites W1986157879 @default.
• W4285394928 cites W1990330436 @default.
• W4285394928 cites W1992139037 @default.
• W4285394928 cites W2029088092 @default.
• W4285394928 cites W2035387023 @default.
• W4285394928 cites W2058734479 @default.
• W4285394928 cites W2060363577 @default.
• W4285394928 cites W2097409998 @default.
• W4285394928 cites W2108051921 @default.
• W4285394928 cites W2124886112 @default.
• W4285394928 cites W2149724135 @default.
• W4285394928 cites W2520630506 @default.
• W4285394928 cites W2523060386 @default.
• W4285394928 cites W2550207834 @default.
• W4285394928 cites W2588068358 @default.
• W4285394928 cites W2595286623 @default.
• W4285394928 cites W2770862842 @default.
• W4285394928 cites W2772964453 @default.
• W4285394928 cites W2790898414 @default.
• W4285394928 cites W2791879821 @default.
• W4285394928 cites W2950747078 @default.
• W4285394928 cites W2981875080 @default.
• W4285394928 cites W3009963727 @default.
• W4285394928 cites W3020990609 @default.
• W4285394928 cites W3024108956 @default.
• W4285394928 cites W3047787772 @default.
• W4285394928 cites W3109472692 @default.
• W4285394928 cites W3128646645 @default.
• W4285394928 cites W3199776789 @default.
• W4285394928 cites W42253793 @default.
• W4285394928 cites W4244315786 @default.
• W4285394928 doi "https://doi.org/10.1111/bcp.15461" @default.
• W4285394928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35831229" @default.
• W4285394928 hasPublicationYear "2022" @default.
• W4285394928 type Work @default.
• W4285394928 citedByCount "0" @default.
• W4285394928 crossrefType "journal-article" @default.
• W4285394928 hasAuthorship W4285394928A5006238207 @default.
• W4285394928 hasAuthorship W4285394928A5014858344 @default.
• W4285394928 hasAuthorship W4285394928A5015387543 @default.
• W4285394928 hasAuthorship W4285394928A5018676268 @default.
• W4285394928 hasAuthorship W4285394928A5022167252 @default.
• W4285394928 hasAuthorship W4285394928A5023510680 @default.
• W4285394928 hasAuthorship W4285394928A5025804381 @default.
• W4285394928 hasAuthorship W4285394928A5033591303 @default.
• W4285394928 hasAuthorship W4285394928A5037441803 @default.
• W4285394928 hasAuthorship W4285394928A5071805546 @default.
• W4285394928 hasAuthorship W4285394928A5080158628 @default.
• W4285394928 hasAuthorship W4285394928A5082379986 @default.
• W4285394928 hasAuthorship W4285394928A5089216656 @default.
• W4285394928 hasBestOaLocation W42853949281 @default.
• W4285394928 hasConcept C112705442 @default.
• W4285394928 hasConcept C121608353 @default.
• W4285394928 hasConcept C126322002 @default.
• W4285394928 hasConcept C143998085 @default.
• W4285394928 hasConcept C2776248978 @default.
• W4285394928 hasConcept C2777909004 @default.
• W4285394928 hasConcept C2908647359 @default.
• W4285394928 hasConcept C526805850 @default.
• W4285394928 hasConcept C71924100 @default.
• W4285394928 hasConcept C99454951 @default.
• W4285394928 hasConceptScore W4285394928C112705442 @default.
• W4285394928 hasConceptScore W4285394928C121608353 @default.
• W4285394928 hasConceptScore W4285394928C126322002 @default.
• W4285394928 hasConceptScore W4285394928C143998085 @default.
• W4285394928 hasConceptScore W4285394928C2776248978 @default.
• W4285394928 hasConceptScore W4285394928C2777909004 @default.
• W4285394928 hasConceptScore W4285394928C2908647359 @default.
• W4285394928 hasConceptScore W4285394928C526805850 @default.
• W4285394928 hasConceptScore W4285394928C71924100 @default.
• W4285394928 hasConceptScore W4285394928C99454951 @default.
• W4285394928 hasFunder F4320322583 @default.
• W4285394928 hasFunder F4320327941 @default.
• W4285394928 hasFunder F4320330267 @default.
• W4285394928 hasIssue "12" @default.
• W4285394928 hasLocation W42853949281 @default.
• W4285394928 hasLocation W42853949282 @default.

• next